Summit Therapeutics (SMMT) Stock Price, News & Analysis

Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and address serious unmet medical needs. The company describes its therapies as patient-, physician-, caregiver- and societal-friendly, reflecting an emphasis on the broader impact of cancer treatment.

Summit was founded in 2003 and its shares are listed on the Nasdaq Global Market under the symbol SMMT. According to company disclosures, Summit is headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, United Kingdom. The company operates within the biotechnology and healthcare sector, concentrating its efforts on oncology drug development.

Oncology focus and ivonescimab (SMT112)

A central focus of Summit’s current pipeline is ivonescimab,> known as SMT112 in Summit’s license territories (North America, South America, Europe, the Middle East, Africa, and Japan) and as AK112 in China and Australia. Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK). It is described as a novel, potential first-in-class investigational bispecific antibody that combines the effects of immunotherapy via blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF in a single molecule.

Summit reports that ivonescimab displays cooperative binding to each of its intended targets, with multifold higher affinity to PD-1 when in the presence of VEGF. The molecule has a specifically engineered tetravalent structure with four binding sites, which the company states enables higher avidity (accumulated strength of multiple binding interactions) in the tumor microenvironment (TME). The design, together with a reported half-life of 6 to 7 days after the first dose and approximately 10 days at steady state dosing (Zhong et al., SITC 2023), is intended to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs targeting PD-1 and VEGF.

Ivonescimab is an investigational therapy that, according to Summit, is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Akeso has reported that ivonescimab was initially approved for marketing authorization in China in May 2024, and that over thousands of patients have been treated with ivonescimab in clinical studies globally and tens of thousands in a commercial setting in China.

Clinical development in non-small cell lung cancer (NSCLC)

Summit began its clinical development of ivonescimab in non-small cell lung cancer (NSCLC). The company has described multiple Phase III clinical trials in NSCLC:

• HARMONi: a multiregional, double-blinded, placebo-controlled Phase III trial evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR tyrosine kinase inhibitor (TKI). Summit reports that HARMONi demonstrated a statistically significant progression-free survival (PFS) benefit for ivonescimab plus chemotherapy compared to chemotherapy alone, with what the company describes as a clinically meaningful hazard ratio and consistent benefit across Asian and Western sub-populations. Overall survival (OS) analyses showed a positive trend without reaching statistical significance in the primary analysis, with longer-term follow-up in Western patients yielding an OS hazard ratio consistent with the primary analysis and an improved nominal p-value.
• HARMONi-3: a Phase III trial intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic squamous or non-squamous NSCLC, irrespective of PD-L1 expression.
• HARMONi-7: a Phase III trial intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Summit has also highlighted data from HARMONi-A, a single-region Phase III trial in China conducted and sponsored by Akeso, evaluating ivonescimab plus chemotherapy versus chemotherapy alone in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after EGFR TKI treatment. According to a Summit-reported summary of Akeso’s results, ivonescimab plus chemotherapy in HARMONi-A demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone, with a reported hazard ratio of 0.74 and a higher median OS in the ivonescimab arm. Summit notes that HARMONi-A was the first Phase III study conducted with ivonescimab and represents the first statistically significant OS benefit achieved by an ivonescimab-containing regimen over a standard-of-care regimen.

Summit has stated that, based on results from HARMONi, it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for ivonescimab in combination with chemotherapy in second-line or later treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC. The company describes this as a setting with high unmet medical need and limited approved options in the United States and other Western territories, and notes that ivonescimab has been granted Fast Track designation by the FDA for the HARMONi clinical trial setting.

Development in colorectal cancer and other solid tumors

Beyond NSCLC, Summit has reported expanding its Phase III clinical development program for ivonescimab into colorectal cancer (CRC). The planned and then initiated global Phase III trial HARMONi-GI3 evaluates ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy in patients with first-line unresectable metastatic CRC. The primary endpoint for HARMONi-GI3 is progression-free survival. Summit has described CRC as an area with limited new options for certain patient groups and has indicated plans to activate clinical trial sites in the United States and other regions.

Summit has also referenced Akeso’s ongoing Phase III studies of ivonescimab in other tumor types, including biliary tract cancer, colorectal cancer, breast cancer, pancreatic cancer, small cell lung cancer, and head and neck cancer. These studies are conducted by Akeso, with Summit holding development and commercialization rights for specified territories, while Akeso retains rights for the rest of the world, including China.

Collaboration and licensing with Akeso and GSK

Summit in-licensed ivonescimab (SMT112) from Akeso Inc. in January 2023. Under this arrangement, Summit reports that it has rights to develop and commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America (including Mexico and all countries in Central America, South America, and the Caribbean), the Middle East, and Africa. Akeso retains development and commercialization rights for the rest of the world, including China, where ivonescimab has been approved in certain indications.

In addition, Summit has announced a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate (risvutatug rezetecan, also known as GSK’227). The collaboration is intended to investigate the combination of ivonescimab and risvutatug rezetecan across multiple solid tumor settings, including small cell lung cancer. Under the terms described by Summit, Summit will supply ivonescimab for the planned study, while GSK will manage day-to-day clinical operations. Each party maintains rights to its respective product, and the agreement is mutually non-exclusive.

Corporate structure, financing, and listing

Summit is incorporated in Delaware and its common stock, with a par value of $0.01 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the symbol SMMT. The company has used both private placements and at-the-market equity offerings as part of its financing strategy.

In an 8-K filing, Summit reported entering into securities purchase agreements for a private placement of common stock to multiple institutional and individual accredited investors, including company insiders and Akeso, for aggregate gross proceeds of approximately $500 million. The company also reported entering into and amending a distribution agreement with a sales agent to offer shares of common stock from time to time under an at-the-market program registered on Form S-3.

Summit has also disclosed inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4), reflecting its use of equity-based compensation for hiring and retention. These options vest in equal annual installments over a four-year period and carry terms described in the company’s announcements.

Facilities and geographic footprint

Summit reports that it is headquartered in Miami, Florida, and maintains additional offices in Menlo Park, California, and Oxford, UK. In an 8-K filing, the company disclosed entering into a sub-sublease for office space in Palo Alto, California, with a term extending several years, indicating an expansion of its physical presence in a major U.S. biotechnology hub.

Research, regulatory, and clinical communication

Summit regularly communicates clinical and corporate updates through press releases and SEC filings. The company has highlighted presentations of ivonescimab data at major scientific and medical meetings, including the World Conference on Lung Cancer, the Society for Immunotherapy of Cancer (SITC), and the European Society for Medical Oncology (ESMO). These communications often summarize Phase III trial designs, endpoints such as progression-free survival and overall survival, hazard ratios, response rates, and safety profiles, as well as regulatory interactions such as BLA submissions and Fast Track designation.

Position within the biotechnology sector

Within the biotechnology and healthcare sector, Summit is positioned as an oncology-focused biopharmaceutical developer with a lead investigational asset, ivonescimab, in late-stage clinical development. Its activities span global Phase III trials, regional collaborations, and licensing arrangements. The company’s disclosures emphasize serious unmet medical needs in NSCLC and CRC and describe ivonescimab’s bispecific PD-1/VEGF mechanism and tetravalent structure as key scientific features under investigation.